- Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
May 13, 2026
Glaukos, a medical technology company focusing on eye disorders, has achieved gains of 20% year to date and 48% over the last year.
Continue Reading
- VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
May 13, 2026
Veeva Systems VEEV recently announced the adoption of Veeva Quality Cloud by Smith+Nephew or Smith & Nephew SNATS SNN to unify and modernize its global quality management operations. The implementation includes Veeva QualityDocs, Veeva QMS and Veeva Training, establishing a centralized quality foundation to support the company’s quality transformation strategy.
VEEV will provide Smith & Nephew with Veeva QualityDocs to serve as a centralized platform for managing controlled quality content, while Veeva QMS will standardize processes, align global operations and enhance collaboration. Additionally, Veeva Training will streamline access to more than 500,000 annual training activities, supporting job and audit readiness.
Management stated that the company is proud to support Smith & Nephew to enhance operational efficiency and expand patient reach through the scalable, end-to-end capabilities of Veeva Quality Cloud. Modernizing quality management processes can support the company’s future growth and innovation initiatives.
Likely Trend of VEEV Stock Following the News
Shares of VEEV have gained 0.1% since the announcement on Monday. In the year-to-date period, shares of the company lost 28.6% compared with the industry’s 22.1% decline. However, the S&P 500 has risen 8.9% in the same timeframe.
The adoption of Veeva Quality Cloud by Smith & Nephew is expected to strengthen Veeva Systems’ position in the growing medtech quality management market. The partnership highlights increasing industry demand for cloud-based quality and compliance solutions that improve operational efficiency and regulatory readiness. Expanding adoption among large global medtech companies, including BioMarin and Roche, could support VEEV’s long-term recurring revenue growth and reinforce its competitive position in enterprise quality management software.
VEEV currently has a market capitalization of $26.02 billion.Zacks Investment Research
Image Source: Zacks Investment Research
More on Veeva Quality Cloud
A major advantage of Veeva Quality Cloud is its ability to eliminate disconnected systems and bring quality processes into a single ecosystem. Veeva QualityDocs provides a centralized system for managing quality, manufacturing, validation and other GxP documents. The platform streamlines document authoring, reviewing, approval and control processes, helping organizations maintain compliance efficiently.
Veeva QMS standardizes global quality workflows, including audits, CAPAs, complaints, supplier management, field actions and change controls. The unified system improves process visibility and supports proactive quality risk management across organizations.
Story Continues
Veeva Training further strengthens compliance by centralizing training records and automating qualification management. Integrated with Veeva QMS and QualityDocs, the solution simplifies training distribution, improves audit readiness and ensures employees remain compliant with evolving regulatory standards.
Industry Prospects Favoring the Market
Going by the data provided by Market Research Future, the healthcare quality management market was valued at $923.5 million in 2025 and is projected to reach $3.22 billion by 2035, expanding at a CAGR of 13.3% from 2025 to 2030.
Factors like the emphasis on value-based care, integration of data analytics, increased focus on patient safety, growing importance of accreditation and rising demand for quality improvement are boosting the market’s growth.
Other News
In March, Veeva Systems acquired Ostro, an artificial intelligence (AI)-powered brand engagement platform designed for the life sciences industry. The platform enables pharmaceutical companies to provide patients and healthcare professionals with real-time, compliant answers through conversational AI on brand websites.
Veeva Systems Inc. PriceVeeva Systems Inc. Price
Veeva Systems Inc. price | Veeva Systems Inc. Quote
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical WST and Globus Medical GMED.
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
May 13, 2026 · zacks.com
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
- Smith & Nephew and Four More Stocks See Action From Activist Investors
May 8, 2026
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Continue Reading
- European Equities Traded in the US as American Depositary Receipts Rise Friday
May 8, 2026
European equities traded in the US as American depositary receipts were higher late Friday morning,
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
- Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
May 6, 2026 · seekingalpha.com
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
- UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
May 6, 2026 · reuters.com
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annual outlook unchanged while announcing a $500 million share buyback.
- Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
May 5, 2026
Smith & Nephew UK Ltd
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.
Demonstrating a long-term commitment to chronic wound management, Smith+Nephew is launching two new wound care innovations designed to support patient outcomes, simplify wound management and ease the clinical burden. This reflects the scale and urgency of a challenge that affects up to 14.9m people in Europe and consumes up to 4% of healthcare spend1. Fully supporting clinicians and patients across the continuum of care, these purpose-built products are set to take on the challenge of chronic wounds, drive better clinical outcomes and get patients back to what they love.
ALLEVYN♢ COMPLETE CARE Foam Dressing has a unique five-layer construction with distinct mode of action capabilities targeted towards both wound management and pressure ulcer prevention. Enhanced ExuLOCK♢ Technology helps lock in exudate and bacteria2,3, releasing up to 100 times fewer bacteria than other foam dressings*4,5. A unique ExuMASK♢ Change Indicator adds confidence to wound healing by minimising strikethrough and is proven to result in longer wear times than other foam dressings6,7, while advanced ShearDEFENSE♢ Unbonded Layer Technology is designed to protect from pressure injuries by dissipating shear forces8.
RENASYS♢ EDGENegative Pressure Wound Therapy System is designed with simplicity at its core. Prioritising effectiveness9, intuition10 and patient discretion11, the lightweight pump supports portability and convenience12, significantly improves wound outcomes**13 and results in an average of 88% therapy session patient compliance14. The modular system’s low-cost maintenance functionality removes annual servicing requirements15 while the intentional design supports patient self-care.10,16
At EWMA (Booth E10), Smith+Nephew is proud to drive progress in next-level healing with an integrated range of wound management solutions designed to prevent early and treat powerfully. Combining interactive workshops with expert-led symposiums prepared in partnership with industry specialists, Smith+Nephew’s evolving portfolio continues to reflect a patient-centric approach that supports early intervention and improved outcomes.
Rohit Kashyap, President of Advanced Wound Management at Smith+Nephew said “With chronic wound management a strategic priority, we are excited to launch ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE System at EWMA. Our ongoing commitment to innovation and collaboration continues to drive progress in patient outcomes, as we shape the future of advanced wound care.”
Story Continues
Find us at EWMA in Booth E10, May 6-8 2026.
To learn more about ALLEVYN COMPLETE CARE Foam Dressing, please click here.
To learn more about RENASYS EDGE tNPWT, please click here.
References:
*Tested in-vitro (bacteria within simulated wound exudate), n=9, 3 batches. Superiority met (p <0.01) dependent on challenge volume tested.
** n=29; p<0.005
1. MedTech Europe. White Paper: Shaping the Future of Wound Care in Europe. Published March 31, 2026. Accessed April 20, 2026. https://www.medtecheurope.org/wp-content/uploads/2026/03/mte-wound-care-paper-final_31.03.2026_compressed.pdf
2. Smith+Nephew 2025. Internal report: CSD.AWM.25.019 V2.
3. Smith+Nephew 2025. Internal report: CSD.AWM.25.008.
4. Smith+Nephew 2025. Internal report: CSD.AWM.25.021 V2.
5. Smith+Nephew 2025. Internal report: CSD.AWM.25.030 V2.
6. Atkinson L, Allen D, Costa B. Poster presented at: European Wound Management Association (EWMA); May 1–3, 2024; London, UK.
7. Milne C, McFee K, Costa B, Askew N, Allen D, Atkinson L. Reduced Clinical and Economic Burden Through Evidence-Based Dressing Selection for Wound Management: Findings From a Systematic Literature Review and Meta-Analysis. Int Wound J. 2026;23 Suppl 1:e70906.
8. Smith+Nephew 2024. Comparison of Frictional Energy Absorber Effectiveness (FEAE) in two five-layer hydrocellular polyurethane foam dressings (HPFD) containing superabsorber and masking layers. CSD.AWM.24.057 V2
9. Vallejo-Carmona L. Structure guided negative pressure wound therapy (NPWT): personalised tissue biomodulation with an NPWT system in adults and older adults. Journal of Wound Care Vol 34, 2025;11
10. Smith+Nephew 2022. RENASYS EDGE System Human Factors Summative Report Summary. Internal Report. CSD.AWM.22.071.
11. Smith+Nephew 2022. How the RENASYS EDGE Negative Pressure Wound Therapy System provides continuity of care to the patient Internal Report. EO.AWM.PCS270.003.V1
12. Smith+Nephew 2022. Summary of footprint, portability, wearability, weight and audible noise for the RENASYS EDGE system. Internal Report. CSD.AWM.22.067.
13. Rossato M, Ryrie M, Robinson M, Searle R, Murdoch J. Use of NPWT as part of a Hospital @ Home wound management service. JCN Wound Care.
14. Smith+Nephew 2025. RENASYS EDGE pump retrospective activity logs analysis, relevant to patient compliance to therapy estimations. Internal Report. CSD.AWM.25.068.
15. Smith+Nephew 2022. Summary of RENASYS EDGE pump cleaning, self-test and maintenance. Internal Report. CSD.AWM.22.068.
16. Smith+Nephew 2023. Summary of RENASYS EDGE Pump Alarms and Alerts bench testing. Internal Report. CSD.AWM.23.017.
Enquiries
Frida Wilhelmsson +46 (738) 499 429
Smith+Nephew frida.wilhelmsson@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
View Comments
- SNN vs. BSX: Which Stock Is the Better Value Option?
May 5, 2026
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Smith & Nephew has a Zacks Rank of #2 (Buy), while Boston Scientific has a Zacks Rank of #4 (Sell) right now. This means that SNN's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
SNN currently has a forward P/E ratio of 13.52, while BSX has a forward P/E of 16.84. We also note that SNN has a PEG ratio of 0.96. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. BSX currently has a PEG ratio of 1.04.
Another notable valuation metric for SNN is its P/B ratio of 2.48. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, BSX has a P/B of 3.24.
These are just a few of the metrics contributing to SNN's Value grade of A and BSX's Value grade of C.
SNN stands above BSX thanks to its solid earnings outlook, and based on these valuation figures, we also feel that SNN is the superior value option right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
May 5, 2026 · globenewswire.com
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.
